Company research

Explore company profiles, quarterly results, announcements and ownership disclosures.

Loading the company view…

BALAXI PHARMACEUTICALS LIMITED (BALAXI) — Stock Analysis

BALAXI PHARMACEUTICALS LIMITED (NSE: BALAXI), ISIN INE618N01022 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.

BALAXI last traded at ₹22.70 (-1.05%), with a 52-week range of ₹15.20 to ₹47.71 (as of 23 Sep 2026).

Shareholding as of Jun 2026: promoters 65.99%, FIIs 0.00%, DIIs 2.56%, mutual funds 0.00%.

EquiSense Score (ECS): 59/100.

Data sourced from NSE and BSE filings. Educational — not investment advice.